Results 31 to 40 of about 2,602 (175)
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study [PDF]
Clinical and Molecular Hepatology, 2017 Background/Aims The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies.
Byeong Wook Cho +9 more
doaj +1 more source
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation [PDF]
, 2012 A recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) can lead to accelerated allograft injury and fibrosis. The aim of this article is to report the first ever use of daclatasvir (DCV; also known as BMS‐790052), a potent orally ...
Alcaide +41 more
core +1 more source
Терапевтический архив, 2017 Aim. To identify predictors for the high efficiency of short-term interferon-containing antiviral therapy (AVT) using direct-acting antivirals (DAAs) in patients with chronic hepatitis C (CHC) virus (HCV) type 1 (CHC-1). Materials and methods. A total of
K Yu Kokina +3 more
doaj +1 more source
Медицинский вестник Юга России, 2017 Objective: to give assessment of the effi cacy and safety of using asunaprevir in combination with daclatasvir in patients with chronic hepatitis C (HCV) with severe fi brosis and cirrhosis.
Elena B. Romanova +5 more
doaj +1 more source
HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors [PDF]
, 2014 Due to error-prone RNA polymerase and the lack of proofreading mechanisms, to the spread worldwide and probable long-term presence in human population, HCV showed a high degree of inter- and intra-subtype genetic variability. Protease inhibitors (PIs), a
CRAXI, Antonio +3 more
core +1 more source
Structure-activity relationships of fluorene compounds inhibiting HCV variants [PDF]
, 2020 Approximately 71 million people suffer from hepatitis C virus (HCV) infection worldwide. Persistent HCV infection causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, resulting in approximately 400,000 deaths ...
Gadhe, Changdev G. +10 more
core +1 more source
Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018 Aim. To estimate efficacy and safety of direct antiviral drugs for hepatitis C treatment in donor lung recipients. Key points. The first cases in Russian literature and one of the first-ever cases of hepatitis C treatment by direct antiviral agents in ...
D. T. Abdurakhmanov +4 more
doaj +1 more source
Журнал инфектологии, 2020 The case of chronic hepatitis C 1b genotype with grade 3 fibrosis according to Metavir, complicated by the development of mixed type III cryoglobulinemia, cryoglobulinemic vasculitis with damage to the skin vessels of the skin (hemorrhagic ...
N. V. Dunaeva +6 more
doaj +1 more source
Annals of Hepatology, 2017 Background: The efficacy and safety of asunaprevir + daclatasvir combination therapy for treatment of hepatitis C virus (HCV) in compensated cirrhotic patients was not fully evaluated in real-world.
Akihiro Tamori +12 more
doaj +1 more source
CD4+T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C viruscoinfected patients [PDF]
, 2017 To characterize peripheral blood natural killer (NK) cells phenotypes by flow cytometry as potential biomarker of liver fibrosis in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients.
Cahn, Pedro +8 more
core +1 more source